Our study establishes a strong mechanistic and functional link between ACVR1 signaling and PRC2, suggesting that the BMP‐ACVR1 pathway may serve as an efficacy biomarker for PRC2 inhibitory drugs in lymphoma patients. Here, ACVR1 is linked to lymphoma.